CT COLONOGRAPHY. CRC TRENDS 1970-1990  Incidence decreased by 7%  Mortality decreased by 20%  Five year survival rates increased by 12%

Slides:



Advertisements
Similar presentations
Colorectal Cancer Awareness in TN: Risk Factors, Screening, Outreach Keith D. Gray, M.D. Assistant Professor of Surgery Division of Surgical Oncology The.
Advertisements

Implementing NICE guidance
Hereditary GI Cancer-a Primer for Medical Oncologists
Colon and Rectal Cancer Update
Colorectal Cancer Screening and Surveillance FDA Advisory Committee March, 2002 David Lieberman MD Chief, Division of Gastroenterology Oregon Health Sciences.
1 An Update on Evolving Colorectal Screening Issues May 19, 2011 This first part today will be presented by: Stanley H. Weiss, MD, FACP, FACE  Professor,
Update on Screening of Gastrointestinal Diseases Niraj Jani, M.D. Greater Baltimore Medical Center 1/30/15.
Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007.
What Everyone Should Know About Colon Cancer Prevention Maria T. Abreu, MD Chief, Division of Gastroenterology Professor of Medicine.
COLORECTAL CARCINOMA Bernard M. Jaffe, MD Professor of Surgery Emeritus.
Colorectal Cancer Ramon Garza III, M.D.. Colorectal CA DNA Sequencing Mismatch Repair Genes Genomics Role of PCR and FISH in Colon CA.
Colorectal Cancer Update Jonathan A. Laryea, MD FACS FASCRS FWACS Division of Colon & Rectal Surgery Department of Surgery University of Arkansas for Medical.
DR Jameel Tariq Miro.  Lifetime incidence 5%  90% of cases occur after age 50  One-third of patients with colorectal cancer die from the disease 
Colorectal Cancer Screening & Surveillance: Anything New? Timothy C. Hoops, M.D.
CT COLONOSCOPY. Turki Alhazmi,MB.CHB, FRCPC, dABR Interventional Radiology-Body MRI Ass. Prof. Faculty of Medicine Umm Al Qura University Makkah-Saudi.
Colorectal Cancer Paula M. Rechner M.D. War Memorial Hospital October 13, 2005.
Colorectal cancer: How do we approach health disparities? Marta L. Davila, MD, FASGE University of Texas MD Anderson Cancer Center.

Screening and Early Diagnosis of Colorectal Cancer
 2 nd overall leading cause of cancer death in the United States › 3 rd in each sex  Approximately 6% of individuals in the US will develop a cancer.
Colorectal Cancer (CRC)
Colorectal Cancer Screening John Pelzel MD Sleepy Eye Medical Center.
Update on Colon Cancer Screening and Prevention
Update on Colorectal Cancer Screening Tests Source: Levin Bernard et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous.
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
A Colonscope is used to remove or biopsy polyps  Night Prep.
A CMH Community DocTalk with Robert Wayne, MD, FACS.
Better Health. No Hassles. Colon Cancer Cancer of the large intestine 112,000 people are diagnosed annually 41,000 new cases of rectal cancer annually.
D. M. Kruss MD Kill the Cancer Do Screening now! Daniel M. Kruss, M.D. Kill the Cancer Do Screening now! Daniel M. Kruss, M.D.
Colorectal Cancer Screening: Considerations and Controversies
Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn’s disease or adenomas NICE CG March 2011.
COLORECTAL CANCER STATISTICS RISK ASSESSMENT SCREENING OPTIONS Luke Crantock.
High risk population in GI field how we can find them? Ahmad Shavakhi MD Associate professor of gastroenterology.
COLORECTAL CANCER SCREENING in December of 2002 Jeffrey W. Frank, MD.
Colorectal carcinoma Dr.Mohammadzadeh.
© Copyright Annals of Internal Medicine, 2014 Ann Int Med. 160 (5): ITC5-1. * For Best Viewing: Open in Slide Show Mode Click on icon or From the View.
CURRENT NATIONAL PREVENTIVE HEALTH CARE GUIDELINES Juanita Halls, M.D. Professor of Medicine General Internal Medicine University of Wisconsin - UW Health.
Screening and Detection in Cancer Survivors
CONFIDENTIAL PillCam ™ COLON PillCam™ COLON has received a CE Mark, but is not cleared for marketing or available for commercial distribution in the USA.
Slides last updated: June 2015 CRC: CLINICAL FEATURES.
Prevention and Health Promotion Administration May Overview of Colorectal Cancer Maryland Department of Health & Mental Hygiene Prevention and Health.
Barium Enema in the detection of Colon Cancer
Dr. Cynthia Walsh Department of Radiology.  To learn the imaging modality best to SCREEN for Colon Cancer  To learn the imaging modality best to SCREEN.
Introduction 30-40% of all cancers arise from the epithelial lining of the aerodigestive tract. 51% & 38% of cancer deaths of men and women are from lung.
Colorectal Cancer.
Better Health. No Hassles. Colorectal Cancer Facts – The 2 nd leading cause cancer-related deaths in the Nation – Highly preventable – Caused 49,920 deaths.
Pathology Report Colorectal Cancer Sahar Najibi April 11 th, 2008.
Cancer Prevention Eyad Alsaeed, MD,FRCPC Consultant Radiation Oncology PSHOC KFMC.
Robert E. Schoen, MD MPH Associate Professor of Medicine and Epidemiology Division of Gastroenterology University of Pittsburgh Organizing Colorectal Cancer.
Screening for Colorectal Cancer (CRC) Nov, 2007 A Aljebreen, FRCPC Division of Gastroenterology KKUH, Riyadh.
Colon Cancer Screening- Rationale Behind the Guidelines.
Slides last updated: March 2015 CRC: RISK FACTORS.
Colorectal Cancer Screening Colorectal Cancer Screening VT SGNA Conference VT SGNA Conference October 24, 2015 October 24, 2015 Lynn Butterly, MD Lynn.
Colonic cancer screening in high risk groups
Colorado Colorectal Screening Program Holly Wolf University of Colorado School of Medicine
CT Colonography vs Colonoscopy for the Detection of Advanced Neoplasia David H. Kim, M.D., Perry J. Pickhardt, M.D., Andrew J. Taylor, M.D., Winifred K.
Interventions for Clients with Colorectal Cancer.
 Our bodies are made of cells, which grow, work, reproduce and die  Genes control when cells grow, work, reproduce and die  Normally, cells obey these.
Colorectal Cancer Sunil T. Joseph, M.D..  Third leading cause of cancer-related death in U.S. (lung)  112,340 estimated new cases in 2007; 52,000 deaths.
Colon Cancer. What is Colon Cancer?  Cancer that begins in the colon or rectum  The colon and rectum are both parts of the large intestine  The third.
POLYPS CHOLORECTAL CANCER M. DuBois Fennal, PhD, RN, CNS.
D. M. Kruss MD Colon Cancer How to nip it in the bud! Daniel M. Kruss, M.D. Colon Cancer How to nip it in the bud! Daniel M. Kruss, M.D.
Colorectal Cancer: Risk Prevention and Diagnosis
Professor Dr. Sabeha Al-Bayati MBCHB,CABM,FRCP
27th Annual Winter CME Conference
Cancer Can Not Comfort But Your Family Can
Colorectal Cancer Screening
Module 4: Colorectal Cancer
VIRTUAL COLONOSCOPY DR DEEPIKA SOLANKI.
Presentation transcript:

CT COLONOGRAPHY

CRC TRENDS  Incidence decreased by 7%  Mortality decreased by 20%  Five year survival rates increased by 12%

COLORECTAL CANCER  Lifetime risk for development 5% or 1:19  Lifetime risk for death : 2.5%  Males slightly higher than females  75% in average risk patients

LIMITED IMPACT Only 37% of cases are diagnosed when the disease is localized 20% will have distant metastases at initial diagnosis

RISK FACTORS  Age > 50 years ((90%)  Familial factors: FAP, Gardner’s, Ashkenazi Jews(APC gene), HNPCC  Racial group : African  Personal or family hx : CRC 2-4x or adenomatous polyp  Personal hx: ovarian, endometrial or breast cancer, chronic IBD > 10 years(UC>Crohn’s)

CRC RISK FACTORS  Low fiber, high fat diet  High red meat consumption  Inactivity, obesity  Smoking  Alcohol

CHEMO-PREVENTION OF CRC  Aspirin, NSAIDS  Postmenopausal estrogen  Calcium, Selenium  Vitamins A, C, E and folic acid

ANATOMIC LOCATION OF CRC Rectosigmoid: 52-61% Ascending colon and cecum 19-24%

SCREENING TESTS FOR CRC How accurate are they?

FIT ADVANTAGES No dietary restrictions Safe, non-invasive, no bowel prep Inexpensive Best study regarding impact on mortality Fewer false positives from upper GI bleed Sensitivity FIT vs gFOBT 82% vs 64% for colorectal cancer 30% vs 41% for adenomatous polyps

FIT DISADVANTAGES  Most cancers bleed intermittently  Most adenomas don’t bleed  non-neoplastic : hemorrhoids, NSAID

COLONOSCOPY High sensitivity and specificity Sensitivity < 5 mm 73% 6-9 mm 87% > 10mm 94% Gold standard for colon evaluation. For an average risk individual with a negative colonoscopy, further screening of any type is not required for 10 years.

COLONOSCOPY- LIMITATIONS  Variable patient compliance  Requires IV sedation  Costly  Time-consuming  Incomplete in 5-10%  CRC localization accuracy 86%

INCOMPLETE COLONOSCOPY  Operator inexperience  Poor bowel cleansing  Redundant bowel  Benign/malignant stricture  Severe diverticulosis

COLONOSCOPY COMPLICATIONS  Perforation dx 1/1000 tx 1/500  Bleeding 3/1000  Death 1-3/ Death rate from colon cancer in yo is 1.8/10000

PERFORATION RATES DCBE 1/25000 CTC 1/22000 FLEX SIGMOIDOSCOPY 1/10000 DIAG COLONOSCOPY 1/1000 THERAPEUTIC COLONOSCOPY 1/500

2009 ACR/CAR GUIDELINES Indications 1) (screening) exam 2) surveillance exam 3) diagnostic exam 4) following incomplete colonoscopy 5) patients at risk for colonoscopy: sedation risk, anticoagulant therapy, prior incomplete colonoscopy, advanced age.

CTC PRO  minimally invasive  low complication rate (perforations 0.46 per 10,000) compared to colonoscopy  no sedation used  usually effective where colonoscopy is technically incomplete  also images extraluminal structures

CTC CON  discomfort  radiation exposure  reduced sensitivity for detection of flat polyps and polyps <6 mm  does not permit biopsy or polyp removal  the accuracy depends on expertise of the radiologist and adequacy of preparation  there are currently no outcome studies regarding CRC mortality prevention

RADIATION  Fixed KVp at 120kv but mA varies  Linear relationship between mA and patient dose  Ultra - low dose ie 10-80mA adequate for colon  Symptomatic patients increase mA for evaluation of extra-colonic findings  Colon ca staging use normal 220 mA for complete exam

2009 ACR GUIDELINES ABSOLUTE CONTRA-INDICATIONS 1. routine f/u of IBD 2. hereditary polyposis or non-polyposis syndromes 3. evaluation of anal disease 4. pregnant patients

2009 ACR GUIDELINES RELATIVE CONTRAINDICATIONS 1. symptomatic acute colitis 2. acute diarrhea 3. recent acute diverticulitis 4. symptomatic colon containing hernia 5. symptomatic or high grade SBO 6. recent colorectal surgery 7. deep biopsy or polypectomy 8. colon perforation

TECHNIQUE Supine and prone imaging Sometimes decubitus IV buscopan Co2 insufflation

BUSCOPAN CONTRA-INDICATIONS  Myastenia gravis  Untreated narrow angle glaucoma  Prostate hypertrophy with urinary retention  Stenotic lesions of the GI tract Megacolon  MI within past 6 months  Tachycardia and angina Congestive cardiac failure

The primary goal of CTC is to detect the precursor lesion of colorectal malignancy

POLYPS 4 types Benign neoplastic ie adenoma Non- neoplastic ie hyperplastic,inflammatory, hamartomatous Only 3% of adenomas will progress to malignancy 30-40% develop an adenoma by 60 yrs

ADENOMATOUS POLYPS Dysplasia- mild, moderate, severe or high grade 3 histologic types: Tubular 85%, < 10mm Tubulovillous 10%, >10mm Villous 5%, 10x increased chance malignancy than tubular, 75%>20mm

ADENOMA-CA PATHWAY Ca risk increases with increasing size of polyp <1% 6-9mm polyp 10% mm polyp 10-50% >20mm polyp

RECOMMENDATIONS BCRS >10mm size - 10% chance malignancy >20mm - 50% chance of malignancy = colonoscopy 6-9mm - f/u CTC in 3 years, 0.7% cancer risk (not warranting colonoscopy/biopsy) if 3 polyps found between 6-9mm size, risk malignancy is equivalent to 10mm polyp ie 10% needs colonoscopy polyps less than 6mm size should not be reported, <0.1% risk malignancy

TUBULOVILLOUS ADENOMA. (A) ENDOLUMINAL 3D VIEW FROM CT COLONOGRAPHY SHOWS A 10- MM PEDUNCULATED POLYP WITH A WELL-DEFINED STALK. (B) AXIAL 2D VIEW SHOWS THE SAME PEDUNCULATED POLYP (ARROWHEAD). UNLIKE MOST OTHER PEDUNCULATED LESIONS, WHICH ARE MORE EASILY RECOGNIZED AS SUCH ON 3D VIEWS, THE STALK AND POLYP IN THIS CASE HAPPEN TO BE ALIGNED IN A STANDARD 2D PLANE.

TUBULOVILLOUS ADENOMA. (A) ENDOLUMINAL 3D VIEW FROM CT COLONOGRAPHY SHOWS A SESSILE, LOBULATED 20-MM POLYP EXTENDING FROM A COLONIC FOLD. (B) DIGITAL PHOTOGRAPH FROM OPTICAL COLONOSCOPY SHOWS THE SAME LOBULATED LESION.

VILLOUS ADENOMA. (A) ENDOLUMINAL 3D VIEW FROM CT COLONOGRAPHY SHOWS A 5-CM IRREGULAR CECAL MASS. THIS PAPILLARY APPEARANCE IS HIGHLY SUGGESTIVE OF A VILLOUS TUMOR. (B) AXIAL 2D IMAGE (WITHOUT ELECTRONIC CLEANSING OF OPACIFIED FLUID) SHOWS THE SAME IRREGULAR CECAL MASS (ARROWHEADS). (C) DIGITAL PHOTOGRAPH FROM OPTICAL COLONOSCOPY SHOWS THE PAPILLARY, FRONDLIKE NATURE OF THE MASS TO GREATER ADVANTAGE. THE LESION WAS NOT MALIGNANT DESPITE ITS LARGE SIZE.

MALIGNANT POLYP. ENDOLUMINAL 3D VIEW FROM CT COLONOGRAPHY IN A SYMPTOMATIC PATIENT SHOWS A LARGE SESSILE MASS, WHICH PROVED TO BE MALIGNANT.

INVASIVE ADENOCARCINOMA. (A) CONTRAST MATERIAL-ENHANCED 2D CURVED REFORMATTED IMAGE WITH SOFT-TISSUE WINDOWING SHOWS AN ANNULAR- CONSTRICTING MASS WITH SHOULDERING (ARROWHEADS) INVOLVING THE SIGMOID COLON. CROSS-SECTIONAL 2D VIEWS ARE MUCH MORE EFFECTIVE THAN ENDOLUMINAL DISPLAYS FOR DEPICTING INVASIVE MASS LESIONS. (B) DIGITAL PHOTOGRAPH FROM OPTICAL COLONOSCOPY SHOWS THE PROXIMAL ASPECT OF THE MASS.

HYPERPLASTIC POLYP. (A) ENDOLUMINAL 3D VIEW FROM CT COLONOGRAPHY SHOWS A 7-MM SESSILE SOFT-TISSUE LESION, WHICH IS INDISTINGUISHABLE FROM AN ADENOMATOUS POLYP. (B) DIGITAL PHOTOGRAPH FROM OPTICAL COLONOSCOPY SHOWS THE SAME SESSILE POLYP. RELIABLE DISTINCTION FROM AN ADENOMATOUS POLYP REQUIRES HISTOLOGIC ANALYSIS.

INTERNAL HEMORRHOIDS. (A) ENDOLUMINAL 3D VIEW FROM CT COLONOGRAPHY SHOWS A LARGE, CIRCUMFERENTIAL MASS AT THE ANORECTAL JUNCTION THAT SURROUNDS THE RECTAL CATHETER. (B) DIGITAL PHOTOGRAPH FROM OPTICAL COLONOSCOPY SHOWS INTERNAL HEMORRHOIDS, WHICH ARE AT LEAST PARTIALLY THROMBOSED, SURROUNDING THE COLONOSCOPE.

SIDE-BY-SIDE COMPARISON OF (INWARD) POLYP AND (OUTWARD) DIVERTICULUM. ENDOLUMINAL 3D VIEW FROM CT COLONOGRAPHY SHOWS A 16-MM TUBULAR ADENOMA (ARROW) ADJACENT TO A WIDE- MOUTH DIVERTICULUM (ARROWHEAD). THE VOLUME RENDERING AND LIGHTING DISPLAY USED HERE ALLOW FOR EASY DISTINCTION.